Raghava Sarma Velagaleti, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heart Failure | 10 | 2022 | 11835 | 0.820 |
Why?
|
Ventricular Dysfunction, Left | 3 | 2024 | 2129 | 0.660 |
Why?
|
Community-Based Participatory Research | 1 | 2020 | 221 | 0.630 |
Why?
|
Hypertrophy, Left Ventricular | 3 | 2013 | 853 | 0.600 |
Why?
|
Heart Ventricles | 4 | 2013 | 3811 | 0.510 |
Why?
|
Ventricular Remodeling | 3 | 2010 | 1259 | 0.460 |
Why?
|
Ventricular Function, Left | 4 | 2022 | 3870 | 0.420 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 1 | 2010 | 151 | 0.350 |
Why?
|
Procollagen | 1 | 2010 | 188 | 0.350 |
Why?
|
Stroke Volume | 3 | 2022 | 5513 | 0.310 |
Why?
|
Myocardial Infarction | 4 | 2024 | 11891 | 0.310 |
Why?
|
Glycemic Index | 1 | 2010 | 396 | 0.290 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2010 | 633 | 0.280 |
Why?
|
Albuminuria | 1 | 2010 | 659 | 0.270 |
Why?
|
Dyslipidemias | 2 | 2010 | 895 | 0.250 |
Why?
|
Creatinine | 1 | 2010 | 1906 | 0.240 |
Why?
|
Natriuretic Peptide, Brain | 2 | 2010 | 1705 | 0.240 |
Why?
|
Echocardiography | 2 | 2013 | 4980 | 0.220 |
Why?
|
Cholesterol, HDL | 1 | 2009 | 1817 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3086 | 0.210 |
Why?
|
Extracellular Matrix | 1 | 2010 | 1726 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3206 | 0.210 |
Why?
|
Coronary Artery Bypass | 2 | 2024 | 2273 | 0.210 |
Why?
|
Angioplasty, Balloon, Coronary | 2 | 2020 | 1880 | 0.200 |
Why?
|
Coronary Artery Disease | 1 | 2022 | 6661 | 0.200 |
Why?
|
Lipids | 2 | 2010 | 3336 | 0.200 |
Why?
|
Exercise | 3 | 2021 | 5783 | 0.180 |
Why?
|
Pandemics | 1 | 2020 | 8621 | 0.180 |
Why?
|
Incidence | 6 | 2020 | 21378 | 0.170 |
Why?
|
Saphenous Vein | 2 | 2020 | 538 | 0.170 |
Why?
|
Death | 1 | 2024 | 678 | 0.160 |
Why?
|
Risk Factors | 10 | 2022 | 74269 | 0.160 |
Why?
|
Plasminogen Activator Inhibitor 1 | 2 | 2010 | 280 | 0.160 |
Why?
|
Cardiovascular Diseases | 4 | 2022 | 15740 | 0.150 |
Why?
|
Pulmonary Ventilation | 1 | 2020 | 371 | 0.150 |
Why?
|
Peptide Fragments | 1 | 2010 | 5120 | 0.150 |
Why?
|
Hypertension | 3 | 2022 | 8595 | 0.140 |
Why?
|
Angioplasty | 1 | 2020 | 360 | 0.140 |
Why?
|
Myocardium | 1 | 2010 | 4688 | 0.140 |
Why?
|
Graft Occlusion, Vascular | 1 | 2020 | 560 | 0.130 |
Why?
|
Male | 20 | 2024 | 359413 | 0.130 |
Why?
|
Angioplasty, Balloon | 1 | 2020 | 597 | 0.130 |
Why?
|
Insulin Resistance | 1 | 2010 | 3960 | 0.130 |
Why?
|
Female | 20 | 2024 | 391011 | 0.120 |
Why?
|
Cardiovascular System | 1 | 2022 | 850 | 0.120 |
Why?
|
Uncertainty | 1 | 2020 | 754 | 0.120 |
Why?
|
Aged | 10 | 2024 | 168995 | 0.120 |
Why?
|
Follow-Up Studies | 5 | 2020 | 39254 | 0.120 |
Why?
|
Middle Aged | 17 | 2024 | 220175 | 0.120 |
Why?
|
Aldosterone | 2 | 2010 | 868 | 0.120 |
Why?
|
Occupational Health | 1 | 2020 | 804 | 0.110 |
Why?
|
Exercise Test | 4 | 2022 | 2125 | 0.110 |
Why?
|
Metabolome | 1 | 2020 | 976 | 0.110 |
Why?
|
Coronary Disease | 1 | 2007 | 5993 | 0.110 |
Why?
|
Humans | 23 | 2024 | 760261 | 0.100 |
Why?
|
Dyspnea | 1 | 2020 | 1352 | 0.100 |
Why?
|
Diabetes Mellitus | 1 | 2010 | 5884 | 0.090 |
Why?
|
Metabolomics | 1 | 2020 | 1626 | 0.090 |
Why?
|
Stents | 2 | 2020 | 3303 | 0.090 |
Why?
|
Comorbidity | 2 | 2020 | 10552 | 0.090 |
Why?
|
Coronary Vessels | 1 | 2022 | 3112 | 0.090 |
Why?
|
Heart Rate | 1 | 2021 | 4169 | 0.080 |
Why?
|
Hemodynamics | 1 | 2020 | 4169 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 1 | 2020 | 6545 | 0.080 |
Why?
|
Heart Function Tests | 1 | 2010 | 319 | 0.080 |
Why?
|
Risk Assessment | 3 | 2020 | 24086 | 0.080 |
Why?
|
Renin | 1 | 2010 | 636 | 0.080 |
Why?
|
Health Status | 1 | 2021 | 4081 | 0.080 |
Why?
|
C-Reactive Protein | 2 | 2010 | 3822 | 0.070 |
Why?
|
Physical Fitness | 2 | 2022 | 732 | 0.070 |
Why?
|
Treatment Outcome | 3 | 2024 | 64947 | 0.070 |
Why?
|
Longitudinal Studies | 2 | 2021 | 14482 | 0.070 |
Why?
|
Cardiac Output | 1 | 2010 | 837 | 0.070 |
Why?
|
Homocysteine | 1 | 2010 | 640 | 0.070 |
Why?
|
Glucose Tolerance Test | 1 | 2010 | 1174 | 0.070 |
Why?
|
Fibrin | 1 | 2008 | 505 | 0.070 |
Why?
|
Cardiomegaly | 1 | 2008 | 593 | 0.060 |
Why?
|
Models, Cardiovascular | 1 | 2010 | 974 | 0.060 |
Why?
|
Predictive Value of Tests | 2 | 2010 | 15273 | 0.060 |
Why?
|
Renin-Angiotensin System | 1 | 2008 | 739 | 0.060 |
Why?
|
Myocardial Revascularization | 1 | 2007 | 841 | 0.060 |
Why?
|
Massachusetts | 2 | 2020 | 8805 | 0.050 |
Why?
|
Diabetes Complications | 1 | 2010 | 1342 | 0.050 |
Why?
|
Body Mass Index | 1 | 2020 | 12901 | 0.050 |
Why?
|
Age Distribution | 1 | 2008 | 2893 | 0.050 |
Why?
|
Prognosis | 2 | 2020 | 29636 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 1 | 2010 | 36247 | 0.050 |
Why?
|
Cohort Studies | 3 | 2010 | 41317 | 0.050 |
Why?
|
Case-Control Studies | 1 | 2020 | 22041 | 0.050 |
Why?
|
Phenotype | 1 | 2020 | 16543 | 0.050 |
Why?
|
Lung | 1 | 2020 | 9989 | 0.050 |
Why?
|
Oxygen | 2 | 2023 | 4189 | 0.050 |
Why?
|
Analysis of Variance | 1 | 2010 | 6242 | 0.050 |
Why?
|
Cholesterol, LDL | 1 | 2009 | 2422 | 0.040 |
Why?
|
Antihypertensive Agents | 1 | 2010 | 2063 | 0.040 |
Why?
|
Regression Analysis | 1 | 2008 | 6361 | 0.040 |
Why?
|
Systole | 1 | 2020 | 947 | 0.040 |
Why?
|
Time Factors | 3 | 2020 | 40133 | 0.040 |
Why?
|
Vascular Patency | 1 | 2020 | 901 | 0.030 |
Why?
|
Coronary Thrombosis | 1 | 2020 | 486 | 0.030 |
Why?
|
Risk | 1 | 2008 | 9629 | 0.030 |
Why?
|
United States | 3 | 2020 | 72363 | 0.030 |
Why?
|
Models, Statistical | 1 | 2010 | 5073 | 0.030 |
Why?
|
Survival Analysis | 1 | 2008 | 10185 | 0.030 |
Why?
|
Ultrasonography | 1 | 2008 | 5960 | 0.030 |
Why?
|
Blood Glucose | 1 | 2010 | 6375 | 0.030 |
Why?
|
Insulin | 1 | 2010 | 6592 | 0.030 |
Why?
|
Electrocardiography | 1 | 2008 | 6413 | 0.030 |
Why?
|
Oxygen Consumption | 1 | 2021 | 1840 | 0.030 |
Why?
|
Exercise Tolerance | 1 | 2020 | 826 | 0.030 |
Why?
|
Proportional Hazards Models | 1 | 2008 | 12532 | 0.030 |
Why?
|
Obesity | 2 | 2023 | 12915 | 0.030 |
Why?
|
Retrospective Studies | 2 | 2013 | 80301 | 0.030 |
Why?
|
Prospective Studies | 3 | 2021 | 54263 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2021 | 5201 | 0.020 |
Why?
|
Disease Progression | 1 | 2007 | 13505 | 0.020 |
Why?
|
Genome-Wide Association Study | 1 | 2010 | 12602 | 0.020 |
Why?
|
Adult | 4 | 2022 | 219847 | 0.020 |
Why?
|
Inflammation | 1 | 2008 | 10757 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 2010 | 25928 | 0.020 |
Why?
|
Blood Pressure | 1 | 2022 | 8523 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2020 | 12412 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2010 | 12281 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2008 | 58947 | 0.010 |
Why?
|
Young Adult | 1 | 2022 | 58673 | 0.010 |
Why?
|